As thousands of delegates prepare to gather in Rio de Janeiro for AIDS 2026, the global HIV response stands at a paradoxical crossroads. While scientific innovation is delivering transformative, long-acting tools for prevention and treatment, a parallel funding crisis—driven by significant disruptions to the U.S. President's Emergency Plan for AIDS Relief (PEPFAR)—threatens to roll back decades of progress.
The Human Cost of PEPFAR Disruptions
Ahead of the 26th International AIDS Conference, new data highlights the severe consequences of recent shifts in U.S. global health policy. The PEPFAR Pulse Study, which surveyed 166 implementing partners across 46 countries, revealed that 52% of partners experienced at least one terminated award. These funding cuts led to the closure of over 1,700 service sites, including 1,010 public health facilities.
The impact is particularly acute for children. A rapid analysis of fiscal year 2025 data showed a 14.2% global decline in children receiving PEPFAR-supported treatment. South Africa was hardest hit, reporting a 45% drop in pediatric treatment support. For clinicians, these findings underscore a growing gap in service delivery for the most vulnerable populations, including key groups who have seen essential clinical care activities permanently halted.
Lenacapavir: A New Era for HIV Prevention
Contrasting these systemic challenges is the remarkable success of twice-yearly injectable lenacapavir for PrEP. New 52-week data from the open-label extension (OLE) of the PURPOSE 1 and 2 studies confirm the drug's high efficacy and safety profile.
In the PURPOSE 1 trial involving cisgender women in South Africa and Uganda, researchers reported zero new HIV acquisitions during the OLE phase. Furthermore, 95.2% of eligible participants chose to switch to or continue with the twice-yearly injection over daily oral options, demonstrating strong patient preference for long-acting modalities.
Similarly, the PURPOSE 2 trial confirmed lenacapavir's efficacy in cisgender men and gender-diverse individuals globally, with only one new acquisition reported during the open-label phase. Experts suggest that if pricing barriers are resolved, lenacapavir could be transformative in curbing the global pandemic.
Once-Weekly Oral Treatment: Addressing Pill Fatigue
For patients currently on antiretroviral therapy (ART), the "pill fatigue" associated with daily regimens remains a significant barrier to long-term adherence. The Phase 3 ISLEND-1 and ISLEND-2 trials may offer a solution: a once-weekly oral single-tablet regimen combining islatravir and lenacapavir.
Results presented ahead of the conference demonstrate that this weekly pill is statistically non-inferior to standard-of-care daily regimens, such as bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). For the first time, clinicians may soon have an oral option that fits more flexibly into a patient's life.
Uncovering Hidden Immune Activity in the CNS
Beyond treatment delivery, AIDS 2026 will spotlight critical findings in HIV cure research. A study of adolescents who have been on ART since infancy found that viral suppression in the blood does not guarantee a "quiet" central nervous system (CNS).
Approximately 19% of adolescents with suppressed blood levels still showed persistent HIV-specific immune activity in their spinal fluid. This activity was most common in those with a history of treatment interruptions. For the medical community, this suggests that monitoring blood viral loads alone may be insufficient for understanding the full scope of the virus's impact on the CNS, particularly in pediatric and adolescent populations.
Future Implications
The scientific highlights of AIDS 2026 demonstrate that the tools to end the HIV epidemic are within reach. However, the recurring theme of the conference—Rethink. Rebuild. Rise.—reflects the urgent need for political and financial stability.
Without a commitment to restoring programs like PEPFAR and ensuring affordable access to long-acting innovations, the clinical benefits of these scientific leaps may remain out of reach for those who need them most.
Reference
- Data revealing the impact of PEPFAR disruptions and advances in long-acting HIV prevention and treatment announced ahead of AIDS 2026.